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KAJIAN KAWALAN RAWAK TERHADAP KEBERKESANAN 
INTERVENSI ‘MOTIVATIONAL INTERVIEWING IN DIABETES AND 
TUBERCULOSIS EDUCATION WITHIN DIRECTLY OBSERVED 
THERAPY (MID-DOT)’ TERHADAP KEJAYAAN HASIL RAWATAN BAGI 
PESAKIT TUBERKULOSIS PARU-PARU YANG MENGHIDAP DIABETES 
DI KELANTAN 
 
Insiden tuberkulosis (TB) di kalangan pesakit diabetes mellitus (DM) di Malaysia 
semakin pesat. Ketidakpatuhan terhadap strategi rawatan merupakan salah satu 
halangan dalam mencapai hasil rawatan TB yang berjaya dan kawalan glisemik yang 
baik. Motivational Interviewing (MI) telah digunakan dalam mempromosikan 
penjagaan kendiri di kalangan pesakit diabetes dan terbukti mampu meransang 
motivasi dalaman pesakit untuk berubah. Tujuan kajian ini adalah untuk menilai 
keberkesanan intervensi MID-DOT terhadap hasil rawatan TB, kawalan glisemik dan 
aktiviti penjagaan kendiri di kalangan pesakit TB yang mempunyai diabetes. Sepuluh 
daerah di Kelantan telah dirawakkan secara berkelompok ke intervensi (5 daerah 
dengan 15 pusat rawatan TB) dan kumpulan kawalan (5 daerah dengan 12 pusat 
rawatan TB). 50 Pesakit TB/DM  direkrut dalam kumpulan intervensi untuk menerima 
program intervensi MID-DOT (pendidikan kendiri penjagaan diabetes and 
tuberkulosis diberikan kepada pesakit setiap minggu selama 6 bulan di mana setiap 
sesi adalah selama 30 minit yang disampaikan oleh jururawat TB dalam program 
DOT) manakala 47 pesakit dalam kumpulan kawalan menerima pendidikan kesihatan 
standard. Hasil kajian yang utama adalah kejayaan hasil rawatan selepas menjalani 6 




penjagaan diri diabetes pada peringkat awal, bulan ke-3 intervensi dan bulan ke-6 
tempoh intervensi diberikan. Analisis utama bergantung kepada ‘Intention to treat’ 
menggunakan ‘Repeated Measure analysis of variance (RM Anova)’. Kejayaan hasil 
rawatan adalah 94% (sembuh 76%, sempurna rawatan 18%) untuk kumpulan 
intervensi berbanding 72.3% (sembuh 53.2%, sempurna rawatan 19.1%) untuk 
kumpulan kawalan dengan [risiko relatif (RR) 1.29; 95%CI 1.56-22.67].  Terdapat 
perbezaan dalam mean HbA1c di antara kumpulan intervensi and kumpulan kawalan 
pada bulan ke enam tempoh intervensi [F(1,58)=16.48, p-value<0.001]. Perbezaan 
mean HbA1c (penurunan) dalam tempoh 6 bulan adalah signifikan bagi kumpulan 
intervensi ( 0.79, 95% CI;0.58-0.99) tetapi tidak signifikan bagi kumpulan kawalan 
(0.03, 95%CI; -0.25,0.30). Pada masa yang sama, terdapat perbezaan dalam mean 
DSCA di antara kumpulan intervensi and kumpulan kawalan [F(1,89)=43.51,p-
value<0.001]. Perbezaan mean DSCA dalam tempoh 6 bulan (penambahan) bagi 
kumpulan intervensi  adalah lebih tinggi (-8.59, 95%CI;-9.98,-7.18) berbanding 
kumpulan kawalan (-0.68,95%CI;-2.06,0.71). Intervensi MID-DOT yang disampaikan 
oleh jururawat TB semasa DOT sebagai tambahan kepada pendidikan kesihatan rutin 
adalah efektif dalam meningkatkan kejayaan hasil rawatan TB serta mencapai 
pengendalian glisemik yang baik dan amalan penjagaan diri diabetes. Strategi TB dan 
DM yang inovatif ini sangat disyorkan untuk ditingkatkan ke seluruh negara untuk 
mengurangkan beban penyakit TB dan diabetes. 
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RANDOMISED CONTROLLED TRIAL ON EFFECTIVENESS OF 
MOTIVATIONAL INTERVIEWING IN DIABETES AND TUBERCULOSIS 
EDUCATION WITHIN DIRECTLY OBSERVED THERAPY (MID-DOT) 
INTERVENTION ON TUBERCULOSIS TREATMENT OUTCOMES 
AMONG PULMONARY TUBERCULOSIS PATIENTS WITH DIABETES IN 
KELANTAN 
 
Incidence of tuberculosis (TB) patients with diabetes mellitus (DM) patients in 
Malaysia is rising rapidly. Non-adherence to treatment strategies has been noted as one 
of the barriers in achieving successful TB treatment outcome and good glycaemic 
control. Motivational Interviewing (MI) has been use in promoting diabetes self-care 
among diabetic patients and proven to stimulate patients’ internal motivation to 
change. the aim of this study was to evaluate the effectiveness of motivational 
interviewing in diabetes and tuberculosis education within directly observed therapy 
(MID-DOT) intervention on TB treatment outcomes, glycaemic control and diabetes 
self-care activities among TB patients with diabetes. Ten districts in Kelantan, a 
northeastern-state in Malaysia, were cluster-randomized into intervention (5 districts 
with 15 TB treatment centres) and control group (5 districts with 12 TB treatment 
centres). Fifty pulmonary tuberculosis patients with diabetes were recruited in the 
intervention group to receive the MID-DOT intervention program (24 sessions of 30 
minutes each comprising face to face diabetes self-care and TB education using MI 
approach every week for 6 months which were delivered by the TB nurses within DOT 
program), while 47 patients in the control group received standard health education. 
The primary endpoint was the proportion of patients achieving successful TB 
treatment outcome after 6-month TB treatment course. Secondary endpoints were the 




baseline, 3rd month and 6th month of intervention period. Primary analysis relied on 
intention to treat using Repeated Measures Analysis of Variances (RM Anova). 
Successful TB treatment outcome was 94% (cured 76%, completed treatment 18%) 
for the intervention group versus 72.3% (cured 53.2%, completed treatment 19.1%) 
for the control group with [Relative risk (RR): 1.29, (95% CI 1.56, 22.67)]. A 
significance difference of mean HbA1c seen between intervention and control group 
at six months of intervention [F(1,58)=16.48, p-value<0.001]. There was a significant 
reduction of HbA1c of three-time points for intervention group while for the control 
group, no significant reduction was observed. Meanwhile, a significance difference 
was also seen in mean diabetes self care activities (DSCA) score between intervention 
and control group [F(1,89) =43.51, p-value<0.001]. The mean difference of DSCA 
over time was significantly higher in the intervention group (-8.59, 95%CI; -9.98, -
7.18) compared to control group (-0.68, 95%CI;-2.06,0.71). MID-DOT intervention 
delivered by TB nurses during DOT session as an adjunct to the standard health 
education was shown to be effective in increasing successful TB treatment outcomes 
as well as achieving good glycaemic control and diabetes self-care practices. This 
innovative dual diseases strategies is highly recommended to be scaled up to 











CHAPTER ONE  
   INTRODUCTION  
 
1.1 The double burden of Tuberculosis and Diabetes Mellitus 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis that 
spreads from person to person through the air (Zumla  et al., 2013). It has the potential 
to affect any part of the body and typically affects the lungs (pulmonary TB) (Golden 
and Vikram, 2005). A bacteriologically confirmed TB case is determined when a 
biological specimen is found to be positive by smear microscopy, culture, or WHO-
approved rapid diagnostics test. A clinically diagnosed TB case is defined as case 
which does not fulfil the criteria for bacteriological confirmation, but rather has been 
diagnosed as active TB by a clinician or other medical practitioner who has decided to 
give the patient a full-course TB treatment (WHO, 2013).  
 
The major goals for TB treatment include curing the individual patient and minimize 
the transmission of Mycobacterium tuberculosis to others in the community. Effective 
treatment of TB requires adherence to a minimum of six-month treatment with 
multiple TB drugs. To improve adherence and cure rates, Directly Observed Therapy 
(DOT) is recommended for the treatment of TB (Bass et al., 1994). DOT is a method 
in which patients are observed and documented ingesting each dose of anti-TB 
medications by a trained health personnel. It forms the cornerstone of the patient-
centred approach recommended by the World Health Organization (WHO) for 
treatment of TB to maximize the likelihood of completion of therapy and help patients 





WHO declared the TB a global public health emergency in 1993. Since then, it has 
intensified efforts to control the disease worldwide (WHO, 1994). Despite these 
efforts, the disease continues to spread, with an estimated 10 million people suffered 
from TB every year (WHO, 2015). In 2016, 6.3 million new cases of TB were reported 
(up from 6.1 million in 2015), equivalent to 61% of the estimated incidence of 10.4 
million. The latest treatment outcome data show a global treatment success rate of 
83%, similar to recent years. In Malaysia, by the end of 2016, 25 739 people had been 
diagnosed with TB (92 in 100 000 population); the latest treatment success rate was 
78% (WHO, 2017).  
 
TB is curable but if left untreated, it can be fatal (Zumla  et al., 2013). Broader 
influences on the TB epidemic includes patient adherence to TB treatment, and the 
complex interaction between other diseases, poverty, racism, socioeconomic policy, 
migration, social stigma, gender, and culture. There is consensus among the scientists 
that health providers and poorly managed health care services have largely attributed 
to poor adherence of TB patient, while TB comorbidities such as HIV and diabetes 
contribute to the rise (Addington, 1979).  
 
Diabetes is known to be a risk factor for TB (Stevenson et al., 2007). During the last 
twenty years, the prevalence of diabetes has increased dramatically in many part of the 
world and the disease is now a worldwide public health problem.  The total number of 
people with diabetes worldwide is projected to rise from 425 million in 2017 to 629 
million in 2045. About 79% live in low and middle-income countries.  In Malaysia, at 




with diabetes (IDF, 2015). However, the prevalence may actually be higher (17.5%) 
according to National Health Morbidity Survey (NHMS) 2015 (NHMS, 2015). 
 
With the advent of diabetes, there has been dramatic resurgences of TB, as both 
diseases are linked at rates of 10-30% (Zheng et al., 2017). A few studies have found 
that diabetes weakens a person's immune system and so increases the risk of developing 
TB. Recent evidence has shown that the relative odds of developing TB are higher in 
diabetics than non-diabetics, with odds ratios (OR) ranging from 2.44-8.33 (Alisjahbana 
et al., 2007; Atif et al., 2014; Jeon and Murray, 2008; Kapur and Harries, 2013). A meta-
analysis showed that the risk of death during TB treatment (RR1.89, 95%CI; 1.52-
2.36) and relapse following treatment (RR 3.89, 95%CI; 2.43-6.23) were both higher 
in TB patients with diabetes compared to those without diabetes. The combine 
outcomes of TB treatment failure and death were also higher (RR 1.69, 95% CI;1.36-
2.12) (Baker et al., 2011).  
 
The clinical management of dual diseases is complex. Good glycaemic control which 
may improve the TB treatment outcomes requires the pharmacological and non-
pharmacological efforts from both patients and health care providers (Riza et al., 
2014). The therapeutic regimens of TB and diabetes medications recommended by 
WHO have been shown to be highly effective, but non-adherence to treatment calls for 








1.2 Problem Statements 
In TB/DM management, non-adherence to treatment strategies has been identified as 
one of the barriers in achieving successful TB treatment outcome and good glycaemic 
control (Addington, 1979; Agarwal et al., 2016; Brown and Bussell, 2011). Adherence 
declined due to lack of motivation. Appropriates style of counselling, repetitive 
education session and person delivered the health education has been recognised as 
major factors that may influenced patients’ motivation to make a behaviour change 
(Barlow et al., 2002). However, the current practice always used traditional 
counselling approach (show and tell) that often forced, taught, and instructed the 
patients to change without notice conflicts within the patient to be obstacles for them 
to change. The patients receiving these methods often report they feel depressed, 
uncomfortable, powerless, so not motivated to be responsible for their own health 
(Miller and Rollnick, 2012).  
 
The task of giving diabetes self-care education in TB/DM management are usually 
given to nutritionists and diabetes educators who only see patients within three to six 
months durations in diabetes clinic. Ideally, this task should have been delivered 
repetitively especially during six months of TB treatment (Tan and Magarey, 2008). 
However, to refer a patient with active TB to a diabetic educator in a separate diabetes 
clinic for a regular/daily counselling is not an appealing option, both from the patients’ 
and infectious control points of view. Patients may refuse a daily referral during their 
TB treatment due to stigma. Diabetes clinics may be equipped for TB infection control. 
There will be a risk of TB cross-transmission to other diabetic patients and healthcare 
workers if TB patients with diabetes are sent for daily diabetes counselling at diabetic 




In the current Malaysian context, although TB staff engage daily with patients during 
DOT, no reinforcement or proper diabetes self-care education is given. A sense of 
responsibility is lacking as staff have not been trained as diabetes educators. Besides, 
there is no current educational materials or guidelines specifically addressing the TB 
and diabetes education to be used by TB staff. Although many diabetes education 
materials and module available in healthcare setting, the complexity of materials 
provided may led patients struggle to understand the self-care points of information of 
their chronic conditions, written medication and translating the knowledge received 
into the daily practice (Albright et al., 1996; Tan and Magarey, 2008).  
 
In the Pacific Islands region, extensive educational materials have been developed by 
novel Hawaiian TB-DM study for TB patients with diabetes (Pyan, 2016). However, 
there are substantial differences in the educational, socioeconomic, and cultural 
backgrounds of TB patients with diabetes in Malaysia as compared to the Hawaiian 
patients. Hence, adoption of related TB and diabetes materials from foreign countries 
to educate TB patients with diabetes in Malaysia is not feasible or practical.  
 
 
1.3 Research gap 
Motivational Interviewing (MI) has been used in smoking cessation and promoting 
medication adherence among TB patients (Louwagie et al., 2014). However, to the 
best of the researcher’s knowledge, no diabetes self-care education trials using MI 
approach have been conducted in a population of TB patients with diabetes, which 
effectiveness may differ because dually infected TB patients may be severely ill or 




Studies relating to glycaemic control among TB patients with diabetes have been 
relatively scanty, and evidence of a causal association between glycaemic control and 
TB treatment outcomes remain limited. Methodologies in previous studies have not 
adequately explained the causal relationship between proper glycaemic control and 
successful TB treatment outcomes. Many evidence come from studies that conducted 
retrospectively with no baseline data of HbA1C so that the temporal relationship and 
causal pathway cannot be assessed (Chiang et al., 2015; Deng et al., 2016; Ruslami et 
al., 2010; Urquhart, 1996). The interventional studies among the TB population 
concerning glycaemic control of diabetes are more focused on drug regimes. 
Therefore, evidence from the field regarding non-pharmacological strategies is 
lacking.  
 
Recent studies concluded that the strategies in controlling glucose and how tightly 
glucose control influences the TB treatment outcomes among TB patients with 
diabetes should be determined. Randomised controlled trials comparing TB treatment 
outcomes, diabetes complication rates and haemoglobin A1C levels in people who 
receive diabetes-specific interventions, in addition to standard TB care to those who 
receive standard TB care, would greatly contribute to building an evidence base for a 




1.4 Justification of study 
A well-structured coordinating mechanism is necessary to adequately respond to the 
growing concern of TB and diabetes comorbidity. Cooperation between diabetes and 
TB services will maximize the efficient use of resources. The current practices on 
diabetes and TB education to TB patients with diabetes should be enhance and need 
improvement. Appropriate education materials, repetitive education from both TB and 
diabetes team, and improvement in counselling for delivering diabetes self-care 
advices are strongly needed during the six months of TB treatment to achieve good 
glycaemic control. 
 
Motivational Interviewing (MI) has been used by dietician and diabetes educator in 
promoting diabetes self-care among diabetic patients and proven to stimulate patients’ 
internal motivation to change. The greater demands for TB nurses with no background 
training as diabetic educator justifies the need of development of MID-DOT training 
module in this study. The training module will help professional or other health care 
practitioners conduct a consistent and effective training for TB staff intended to help 
them in creating a focus, repetitive and structured TB and DM education during DOT. 
Such a module can serve as reference material in every TB centre in Malaysia to guide 
TB staff in positive counselling practice. Culturally appropriate educational materials 








Operational research will be conducted to assist in delivering TB and diabetes self-
care education at TB clinic by trained TB nurses during patient visits for daily intake 
of TB drug (Directly Observed Therapy) during the six months of the TB treatment 
courses. This TB and diabetes self-care education will be delivered using MI style, 
which follows the standardized intervention module (MID-DOT training module) and 
educational materials principally developed for this study.  
 
This study will address the research gap on alternative strategies for management TB 
patients with diabetes. The findings will delineate some important aspects on the effect 
of innovative intervention using standardised module and educational materials on TB 
treatment success through lifestyle modification, glucose monitoring, and medication 
adherence. It also contributes to the body of literature in the field of association 
between diabetes, glycaemic control and TB treatment success and help researchers to 
have a deeper understanding and to clarify the temporal relationship or causal pathway 
between glycaemic control and TB treatment success. 
 
This study will also increase stakeholder attention to and awareness of the benefits of 
implementing shared responsibilities between diabetes and TB teams in delivering 
health education concerning both diseases, especially during 6 months of TB 
treatment. This study is intended to facilitate more powerful integration programs that 
can enhance the current strategies among local health authorities.  Future researchers 
may use this research as a guide to methodology for conducting operational research 






1.5 Research questions 
This study addresses the following research questions: 
1. Does the MID-DOT intervention program effective in  increasing successful TB 
treatment outcome among pulmonary TB patients with type 2 diabetes in 
Kelantan. 
2. Does the MID-DOT intervention program effective in  achieving good glycemic 
control during TB treatment among pulmonary TB patients with type 2 diabetes 
in Kelantan. 
3. Does the MID-DOT intervention program effective in  achieving good diabetes 
self-care practices during TB treatment among pulmonary TB patients with type 




1.6.1 General Objectives 
To evaluate the effectiveness of MID-DOT intervention on successful TB treatment 
outcome including glycaemic control and diabetes self-care practices among 
pulmonary TB patients with type 2 diabetes in Kelantan.     
                      
1.6.2 Specific Objectives 
1. To compare the successful of TB treatment outcome between MID-DOT 
intervention group and usual care group for among pulmonary TB patients with 




2. To compare mean HbA1c level over time between MID-DOT intervention group 
and usual care group among pulmonary TB patients with type 2 diabetes in 
Kelantan. 
3. To compare mean diabetes self-care activities score over time between MID-DOT 
intervention group and usual care group among pulmonary TB patients with type 
2 diabetes in Kelantan. 
 
1.7 Hypothesis  
1. The MID-DOT intervention program is effective in increasing successful TB 
treatment outcome in comparing to standard health education among pulmonary 
TB patients with type 2 diabetes mellitus in Kelantan. 
2. The MID-DOT intervention program is effective in achieving  good glycemic 
control (reduction in HbA1c level) in comparing to standard health education 
among pulmonary TB patients with type 2 diabetes mellitus in Kelantan. 
3. The MID-DOT intervention program is effective in achieving good diabetes self-
care practices (improvement of score) in comparing to standard health education 










LITERATURE REVIEW  
 
2.1 Understanding Tuberculosis and Diabetes 
TB has been described with the terms “consumption”, “white plague” and "phthisis" 
throughout the history (Dubos and Dubos, 1952). The Mycobacterium tuberculosis 
bacteria was discovered in early 1900, but the signs and symptoms of TB have been 
observed as far back as 2400 B.C. Over the past century, there has been a dramatic 
increase in TB rates, despite the availability of advance screening, diagnostics, and 
pharmacological treatment (Metcalf, 1991). Overall, a relatively small proportion (5–
15%) of the estimated people infected with Mycobacterium tuberculosis will develop 
TB disease during their lifetime. However, the probability of developing TB disease 
is much higher among people infected with HIV, and also higher among people 
affected by risk factors such as under-nutrition, diabetes, smoking and alcohol 
consumption (Zumla  et al., 2013). 
 
Based on WHO surveillance data, an estimated 10.4 million people were infected with 
TB in 2016. 90% were adults, 35% were female, 10% were people living with HIV 
and 56% were in five countries: China, Indonesia, India, the Philippines, and Pakistan. 
There were an estimated 1.3 million TB deaths among HIV-negative people (down 
from 1.7 million in 2000) and an additional 374 000 deaths among HIV-positive 
people. About 600 000 new cases were resistance to rifampicin (RRTB), the most 
effective first-line drug, 490 000 of which had multidrug-resistant TB (MDR-TB). In 




per 100,000 populations with a reported 1414 TB deaths (excluding TB-HIV 
mortality), giving rise to 4.9 TB deaths per 100,000 populations (WHO, 2017). 
 
TB is also a costly disease which has a terrible economic impact. Approximately 75% 
to 80% of TB cases are in the economically productive age group. The economic 
impact of TB comes from the large direct and indirect costs incurred by the patients, 
suffered because of loss of income following the inability to work and premature 
deaths. Lengthier treatment, often in hospitals, substantially increases health care costs 
and economic burdens on families and society. Studies in some developing countries 
found that the average cost for treatment of susceptible TB was in the range of USD 
276-154 and USD 1,000-10,000 for MDR-TB. The cost of treating a single case of 
MDR-TB or XDR-TB can be thousands of times more expensive than treating drug-
sensitive TB (Kang et al., 2006; Laurence et al., 2015; Schnippel et al., 2013). A local 
study in Penang showed that the cost of treating TB per patient was RM 3482.30. The 
cost of anti-TB drugs constituted the highest proportion of the cost to the public 
services (31.7%), while the cost to the patient constitutes 80% of the total costs of 
treatment (Elamin et al., 2008). 
 
TB treatment outcomes after 6 months of full course of TB regimens are categorised 
as cured, completed treatment, interrupted treatment, failed treatment and died. In 
1993, the WHO introduced surveillance of TB treatment outcomes to evaluate the 
impact of TB control programs. Treatment success rate, consisting of cured and 
completed treatment, is an important indicator of national TB control programs, with 
the set target of 85% (WHO, 2003b). In 2000, the worldwide rate of TB treatment 




proven adherence strategy to reduce the development of drug resistance, treatment 
failure, or relapse after the end of TB treatment. Good case management, which 
includes establishing a relationship with the patient and addressing barriers to 
adherence, facilitates successful DOT (Alwood et al., 1994; Chaulk et al., 1995; 
Walley et al., 2001; Zwarenstein et al., 1998). 
 
The TB treatment success rate in Malaysia declined from 78% in 2000 to 48% in 2006 
but increased back after 2007. However, the TB treatment success rate has not reached 
the 85% target rate set by the WHO. The National Strategic Plan to Control TB 2011-
2015 was implemented to strengthen and enhance all activities to reduce burden of TB 
disease and increase the TB success rate in the country (MOH, 2012). However, due 
to natural history and complexity of TB disease, treating TB in immunosuppressed 
groups such as diabetes mellitus (DM) and chronic renal failure (CRF) becomes a 
major challenge in reducing TB burden. Among several risk factors for TB, which 
include malnutrition, alcoholism, HIV/AIDS and silicosis, diabetes has only recently 
been appreciated as the number of TB  patients with diabetes is higher than the number 
of patients with TB-HIV co-infection around the world (Aravindalochanan et al., 
2012; Dooley and Chaisson, 2009; Ottmani et al., 2010; Ruslami et al., 2010). 
 
As type 2 diabetes increases globally, it is even more likely to adversely affect TB care 
and control as the prevalence of diabetes are expected to rise dramatically in the 
resource-poor areas where TB thrives. An estimate of  450 million people had diabetes 
worldwide and this number is anticipated to reach 630 million people by 2040 (IDF, 
2015). Eighty per cent of them live in low and middle-income countries in the 




to have the greatest numbers of people living with diabetes by 2035 (China, India, 
Brazil, Indonesia, Pakistan and Russian Federation) are also classified as high TB-
burden countries (WHO, 2016).  
 
With the increased number of diabetes patients among low-resource health care 
systems, TB and diabetes comorbidity will inevitably increase as 10-30% of TB cases 
estimated to be attributable to diabetes (Balakrishnan et al., 2012; Chang et al., 2011; 
Stevenson et al., 2007). Recent studies elsewhere and Malaysia demonstrated the 
prevalence of diabetes among TB patients is ranging from 13 to 36% (Alisjahbana et 
al., 2007; Atif et al., 2014; Bacakoğlu et al., 2001; Balakrishnan et al., 2012; Delgado-
Sanchez et al., 2015; Gil-Santana et al., 2016; Hemming et al., 2011). These 
prevalence vary according to the setting possibly attributable to difference in 
background prevalence of diabetes between populations and methods of screening and 
diagnosing diabetes (Workneh et al., 2017). Studies all over the world also constantly 
reported strong association between diabetes and development of active TB. A 
systematic review of the literatures identified 13 quantitative, age adjusted, 
observational studies in North America, Russia, UK, Korea, Mexico, Taiwan and India 
found that diabetes was associated with an increased risk of TB; across three cohort 
studies, the pooled relative risk of TB associated with diabetes was 3.1, while in case-
control studies the odds ratios of TB ranged from 1.16 to 7.83 (Jeon and Murray, 2008). 
 
Diabetes has certain characteristics that may make diabetes patients more prone to TB 
and suffer worse TB treatment outcomes (Zheng et al., 2017). These characteristics 
are probably a result of internal factors (e.g. low immune system) and external factors 




like impaired cell-mediated immunity, micronutrient deficiency, pulmonary micro 
angiopathy and renal insufficiency, all of which predispose TB patient with diabetes 
to have 3 times higher risk to develop TB, 2 times higher risk of remaining culture 
positive, 4 times higher risk of relapse after completed treatment, and 5 times higher 
risk of death during TB treatment, as compared to those without diabetes (Baker et al., 
2011; Jeon and Murray, 2008; Stevenson et al., 2007).  
 
The Diab-Care Asia project, a cross sectional survey of 24,317 diabetic patients from 
Bangladesh, China, India, Indonesia, Malaysia, Philippines, Singapore, South Korea, 
Sri Lanka, Taiwan, Thailand and Vietnam found that almost 60% of patients had 
values of HbA1C exceeding 8% (Chuang et al., 2002). This poor glycaemic control 
may contribute to the burden of TB incidence worldwide, threaten the TB control and 
overwhelm the capacity of healthcare systems in low and middle-income countries 
around the world (Bailey et al., 2016). This also will in turn hamper WHO’s target to 
scale down global TB incidence by 90%, or less than 10 cases per 100,000 population, 
in 2035 and will further impede the world’s long-term vision of eliminating TB as a 
public health concern by reducing TB rates to less than 1 case per million people by 
2050 (WHO, 2015). 
 
Recognizing this double burden, the WHO and the International Union Against 
Tuberculosis and Lung Disease (The Union) have developed a collaborative 
framework that can help countries mount a response. This framework set out the 
principle of ‘bidirectional screening’; screen TB patients for diabetes and in context 
where TB is common, screen people with diabetes for TB (WHO, 2011). The Union 




co-epidemic of diabetes and TB in Bali in November 2015. Bringing together 
government representativeness, civil society group and other stakeholders from the 
global health community, the convention culminated with the signing of the Bali 
Declaration, a unified agreement to act. Key actions include the implementation of the 
“Collaborative Framework”, supporting the training of health personnel, increasing 
public awareness about both diseases through repetitive education, internal advocacy 
in national and international forums and update, elimination of stigma around TB and 
diabetes, supporting policymaking and research activities, and coordinated 
management in diabetes and TB for good glycaemic control among TB patients with 
diabetes.  
 
Although several strategies and frameworks address diabetes, achieving optimum 
glycaemic control is hard in diabetes patient. This is dependent on the quality health 
care system, financial affordability, patients’ behaviour, self-empowerment, and the 
natural history of both disease. The underlying TB may complicate the glucose control 
in diabetes patient. TB is curable, but the infection increases body catabolism and 
raises blood sugar, making diabetes more difficult to manage. Rifampicin (one of the 
key drugs in any anti-TB regimen) may itself have hyperglycaemic effects that threaten 
glycaemic control (Riza et al., 2014).  
 
Additionally, type 2 diabetes is a lifestyle disease with the glycaemic control 
influenced by multiple risk factors such as imbalance dietary intake, low physical 
activity, smoking, and alcohol intake. Recently, researcher have shown adherence to 
lifestyle modification is helpful in achieving good glycaemic control instead of 




adherence to treatment strategies, health personnel play a crucial role in improving 
patient’s knowledge, self-care and internal motivation. Their competency in delivering 
advice, style of counselling, their frequent meets with the patients might influence 
patient’s interest to make a sustain behavioural changes (Ottmani et al., 2010).  
 
2.2 Perspectives on patient adherence  
 
2.2.1 Definition and context 
Adherence is defined as the extent to which a person’s behaviour taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider (Urquhart, 1996). Adherence differs 
from compliance in the sense that adherence requires the patient’s decision support 
and agreement to the provider’s recommendations (Horne et al., 2005). Patients should 
be actively collaborated with health care providers in their own care and that good 
rapport and communication between patient and health care providers is necessary for 
an effective practice. Adherence always refers to non-communicable diseases such as 
hypertension and diabetes; however, infectious disease such as HIV and TB require 
similar levels of attention and care as many other chronic non-communicable diseases 
due to their chronic nature (McNabb, 1997). 
 
In terms of TB control, adherence to treatment may be defined as the extent to which 
the patient’s history of therapeutic TB drug-taking coincides with the recommended 
and prescribed treatment (Munro et al., 2007). In TB patients with diabetes, adherence 
may extent to their behaviour on following diet and other lifestyle changes. The 




definitions. Outcome oriented definitions use the end-result of treatment, e.g. 
completed and cure rate, as the indicator of success. The process oriented definition 
makes use of intermediate variables such as pill counts to measure adherence and 
appointment-keeping as well as their diabetes self-care activities (Urquhart, 1996) . 
Ideally, adherence to TB treatment should be measured in terms of both quantity and 
timing of the medication taken by the patient. This approach is always practical at the 
individual level, but a more pragmatic approach is needed at the population level. 
Thus, the success of treatment, that is, the sum of the patients who are cured and those 
who have completed treatment under the directly observed therapy, short course 
(DOTS) strategy, is a pragmatic proxy serving as an indicator of treatment adherence 
(Urquhart, 1992). 
 
2.2.2 Factors that influence adherence to treatment 
Previous studies have reported that patients’ sociodemographic characteristics, their 
relationship with health care providers and the regimens offered have been associated 
with adherence to TB treatment (Sumartojo, 1993). The barriers to a good adherence 
to TB treatment can be classified as shown below. 
 
A. Economic and structural factors 
Those afflicted by TB are typically homeless, poor, and/or unemployed. These groups 
are hard to reach as they may have unstable living circumstances and lack effective 
social support networks. This creates an unfavourable environment for ensuring 






B. Patient-related factors 
Age, gender and ethnicity have been linked to treatment adherence in many countries 
(Diwan and Thorson, 1999; Farmer, 1996; Hudelson, 1996). Self-belief in the efficacy 
of TB drugs and knowledge about TB will influence whether or not a patient chooses 
to complete treatment (Dick and Lombard, 1997).  
 
C. Supportive relationships between the health provider and the patient 
Patient satisfaction with the “significant” health care has been shown to be an 
important determinant of adherence (Lewin et al., 2001; Steyn et al., 1997), but good 
and empathic relationships are difficult to forge in situations in which health providers 
are overworked, untrained, unsupported in their tasks, or inadequately supervised, 
common scenarios in countries with a high TB burden (Steyn et al., 1997). 
 
D. Pattern of health care delivery 
Factors related to the organization of clinical services, including availability of 
expertise, links with patient support systems, and flexibility in the hours of operation, 
also affect adherence to treatment. Many ambulatory health care settings responsible 
for the control of TB are organized to provide care for patients with acute illnesses, 
and staff may therefore lack the skills required to develop long-term management plans 
with patients. Consequently, the patient’s role in self-management is not facilitated 







2.2.3 Type of adherence strategies  
Numerous measures and strategies have been introduced in various settings to improve 
patient adherence to treatment. These strategies vary according to whom or what they 
are targeting for change. Certain strategies target patients directly while aiming to 
influence adherence indirectly by targeting other actors or factors for change. They 
may target patients, health providers, the relationship between health providers and 
their patients, the treatment, patients' social contexts or the health system for change 
(Hunt and Arar, 2001; Kidd and Altman, 2000; Sbarbaro, 1979; Vermeire et al., 2001). 
In TB context, the interventions for improving adherence rates may be classified into 
the following categories: 
 
1. Staff supervision and motivation: management process and training aimed at 
improving the way in which providers care for patients. 
2. Defaulter action: the action to be taken when a patient fails to keep a pre-
arranged appointment. 
3. Prompts: routine reminders for patients to keep pre-arranged appointments. 
4. Health education: provision of information about TB and the need to attend 
treatment. 
5. Incentives and reimbursements: money or cash in kind to reimburse the 
expenses of attending the treatment centre, or to improve the attractiveness of 
visiting the treatment centre. 
6. Contracts: agreements (written or verbal) to return for an appointment or 




7. Peer assistance: people from the same social group helping someone with 
tuberculosis to return to the health centre by prompting or accompanying him 
or her. 
8. Directly observed therapy (DOT): an identified, trained and supervised agent 
(health worker, community volunteer or family member) directly monitors 
patients swallowing their anti-TB drugs  (WHO, 2003a). 
 
2.3 Directly Observed Therapy 
Directly observed therapy (DOT) was first developed by Wallace Fox in the 1950s 
with the concept of “entirely supervised administration of medicines”. DOT was first 
adopted in TB drug trials in Madras (India) and Hong Kong as early as the 1960s  and 
is now widely recommended for the measures to promote adherence to TB treatment 
(Bayer and Wilkinson, 1995; WHO, 2003b). DOT has always meant much more than 
“supervised swallowing”. Projects in countries with a high prevalence of TB have 
shown that removing the socioeconomic barriers to DOT faced by patients increases 
both adherence and cure rates (Farmer, 1996; Olle-Goig and Alvarez, 2001). In 
countries where the prevalence of TB is low, such as the United States, DOT 
programmes are complex but highly cost-effective and have several components, 









Since 1991, WHO has promoted the strategy of “directly observed therapy, short 
course” (now known as the DOTS strategy). “DOTS” is the brand name for a 
comprehensive technical and management strategy consisting of the following five 
elements: political commitment; case detection using sputum microscopy among 
persons seeking care for prolonged cough; standardized short courses of chemotherapy 
under proper case-management conditions including DOT; regular drug supply; and a 
standardized recording and reporting system that allows assessment of individual 
patients as well as of overall programme performance (WHO, 2002). 
 
2.4 Patients education and adherence to TB treatment  
 
2.4.1 Patient education 
Patient education has been defined as a deliberate process of influencing patient 
behaviour and producing the changes in knowledge, attitudes, and practices necessary 
to maintain or improve health. The aim of patient education is to implement it as a 
holistic process with the goal of changing the behaviour of the patient and his or her 
family to improve and benefit their own health. Patient education is an assignment that 
all health care workers are responsible (Lorig, 1996).  
 
Patients not following professional health advice is a worldwide challenge for health 
care (Haynes et al., 2008). A growing number of drugs have been shown to 
significantly improve health if taken as recommended, but according to the WHO, only 
about 50% of professional health advice is actually taken up by patients (WHO, 2002). 
Other authors have estimated that the proportion of patients that do not follow doctors' 




a wide-ranging impact. From a public health perspective, it often adds to the burden 
of disease and the pool of infection.  
 
In TB context, non-adherence to drug treatment for tuberculosis has the potential to 
impact negatively on both the individual patient and on the broader health of the 
community. It is therefore important to evaluate which interventions are effective in 
supporting adherence and completion of tuberculosis drug treatment regimen. In 
diabetics, poor adherence causes poor glycaemic control and increase risk of diabetes 
complication. This also increases the financial burden placed on public health services 
and wastes (Haynes et al., 2008). 
 
For health providers it is a source of major frustration and can consume a great deal of 
time and energy (Vermeire et al., 2001). It also impacts negatively on patients' health 
and perhaps also their well-being, particularly patients with long-term illnesses 
(Cleemput et al., 2002). From a research point of view, poor adherence makes clinical 
trials more difficult and costly to administer and the trial results become less 
meaningful (van Hoorn et al., 2016). 
 
2.4.2 Patient centred approach  
A patient-centred approach has been proposed as a way of enhancing the quality and 
outcomes of interactions between health providers and patients. According to a 
systematic review Lewin et al. (2001) most interventions to promote a PCA have been 
directed at primary care physicians in community or hospital outpatient settings. This 
review also found that patient-centred interventions may have a positive impact on the 




the systematic review, some have suggested that there is evidence of a relationship 
between effective provider-patient communication and improved health outcomes 
(Stewart, 1995). Thus, the link between improved provider-patient communication and 
treatment adherence is not entirely clear.  
 
Little is known about the feasibility of implementing a PCA with nurses in busy 
primary health care facilities in developing country contexts or about how this type of 
approach is received by health providers and patients in these contexts. The results of 
one study that explored this in the context of family planning services in Egypt indicate 
that this type of approach can be feasible, acceptable and associated with better health 
outcomes in a less developed country setting (Abdel-Tawab and Roter, 2002). 
 
2.4.2.1 Motivational Interviewing (MI) 
Motivational interviewing(MI) is defined as "a directive, client-centred counselling 
style for eliciting behaviour change by helping clients to explore and resolve 
ambivalence" (Miller and Rollnick, 2012). It is an evidence based, collaborative, 
guided approach to health behaviour change. In contrast to traditional approaches of 
behaviour change, MI embodies respect for the patient. It fosters collaboration 
between the health care provider and patient, demonstrates compassion, and 
emphasizes the patients’ personal autonomy while building self-efficacy (Markland et 
al., 2005; Rubak et al., 2005). Express empathy through active listening, roll with 
resistance, avoid arguing with the patient, resolve the patients’ ambivalence and 
support self-efficacy by emphasizing the autonomy are the spirit and principle of MI.  
 
